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Tumor-associated macrophages, or TAMs, make up a significant component of the tumor 
microenvironment and contribute to the human immune response to cancer. TAMs can either 
take a pro-tumorigenic form, promoted by pro-inflammatory cytokines, that facilitates tumor 
growth and metastasis through the formation of new blood vessels, or an anti-tumorigenic form, 
promoted by interferons and lipopolysaccharides, that recognizes cancerous cells as malignant 
entities for destruction. This investigation seeks to explain how macrophages affect the body’s 
response to cancer and how understanding these mechanisms can be used to develop anti-cancer 
therapeutics. Several different therapeutic strategies that focus on TAMs are detailed, including 
biophosphonate therapy to prevent macrophage production, altering levels of cytokines (i.e., 
CCL2, CXCL12, CSF-1) and adipocytokines to prevent macrophage recruitment, repolarizing 
macrophages to an anti-tumorigenic form, limiting vascular endothelial growth factor (VEGF) 
production by macrophages, and inducing apoptosis in M2 macrophages with minigene vaccines 
or engineered apoptotic agents. There are many exciting possibilities for research in this rapidly 
evolving field, and the hope is that future research will get us one step closer to making cancer 
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“Cancer” is an umbrella term used to refer to several diseases that cause unregulated cell 
replication and division within the body. These diseases typically start in a single body zone, for 
example, the heart or lungs. This uncontrolled cell division often leads to the formation of 
tumors. Tumors are masses of cells that form solid “lumps” that can sometimes be detected from 
the surface. Though many tumors are benign and do not contain cancerous cells, this project will 
focus on cancerous tumors, specifically. Cancer cells are unique in their ability to metastasize. 
NIH’s National Cancer Institute defines metastatic cancer as having “spread from the place 
where it first started to another place in the body.” This means that if an individual develops 
cancer in a primary location such as the breast, it may potentially spread to new locations within 
the body and continue growing cancerous cells. Metastasis not only makes cancer more difficult 
for healthcare providers to locate on a patient, but also makes it significantly more difficult to 
treat. If a cancer has metastasized, it requires treatment both to shrink or remove the existing 
tumors as well as prevent cancerous cells from spreading to even more locations within the body. 
Metastasis is responsible for approximately 90% of modern cancer deaths (Seyfried and 
Huysentruyt 2013). For example, the Mayo Clinic states that only 5% of patients with metastatic 
lung cancer will survive for longer than 5 more years (Mayo Clinic Staff 2020). Not only is 
cancer an issue for human health and rights, but it also ties into the economy, with approximately 
$80.2 billion spent in the US alone on cancer-related medical costs (American Cancer Society 
Medical Content Team 2018). Only by studying the details of the cellular functions of cancer and 
the human immune response to these functions can we learn how to effectively treat cancers. 
 
The goal of this thesis was to develop a better understanding of the different therapeutic 
approaches to cancer that are available. To accomplish this, I began working in the laboratories 
5 
 
of Drs. Maryam Ahmed and Darren Seals, studying tumor-associated macrophages (TAMs), 
podosome development, and oncolytic virotherapy. The overarching goal of the work continuing 
in this laboratory is to determine the efficacy of vesicular stomatitis virus (VSV) as a potential 
oncolytic virotherapy. For my project, I investigated the ability of polarized tumor-associated 
macrophages to produce podosomes and how the number of podosomes produced changes with 
VSV infection. From this initial research, I became familiar with macrophages and their role in 
the tumor microenvironment, and subsequently developed this thesis to further investigate and 
better understand other types of TAM-targeted therapeutic approaches.  
 
A. The Tumor Microenvironment  
Studying cancer in the human body requires a focus on more than just the cancerous cells 
themselves. Studying the cells surrounding tumors and the way these cells interact with the 
tumor is necessary to gain insight as to how the tumor can obtain the resources it needs to 
develop while effectively evading the immune response. Understanding these complex 
interactions requires investigating the cancer environment at the cellular and molecular level. 
The tumor microenvironment (TME) refers to the cancerous cells, immune cells, and 
extracellular matrix in the area surrounding and including the tumor. It “is comprised of 
proliferating tumor cells, the tumor stroma, blood vessels, infiltrating inflammatory cells, and a 
variety of associated tissue cells” (Whiteside 2008). The cells within the tumor 
microenvironment play a large role in the development and behavior of tumor cells, including 
their ability to metastasize. One of the body’s primary responses to the presence of a tumor is the 
activation of an inflammatory response. This response aims to attack the tumor by creating a 
hypoxic environment that prevents cell survival and encourages release of inflammatory cells 
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such as macrophages (Whiteside 2008). However, over time the presence of inflammatory cells 
leads to the production of reactive oxygen species and pro-tumor cytokines. Therefore, the initial 
inflammatory response to a tumor, if sustained over a long period of time, becomes a mechanism 
to prolong the survival of the tumor. The components of the immune response within the tumor 
microenvironment and the roles that they fulfill subvert our expectations of what the immune 
system is and what it does. While immune cells protect our bodies from pathogens and other 
invaders, the human immune system is just as capable of furthering diseases that can lead to 
sustained damage.  
 
B. The Immune Response to a Non-Foreign Invader 
 
When the body senses a foreign or unusual substance in the body such as bacteria, 
viruses, or cancer, the immune response is triggered. This involves the development, 
proliferation, migration, and activation of several different cell types. The human immune 
system can be divided into two subsystems, the innate immune system and the acquired immune 
system. The innate immune system is composed of cells and proteins that the body has produced 
as a response to foreign invaders since birth. These cells form the “general” immune response 
that is dependent on white blood cells found throughout the body to target and kill pathogens. 
The acquired (or adaptive) immune system is generated after the initiation of the innate immune 
responses and consists of cells that respond to specific pathogens. The cells in this system can 
“remember” antigens that the body has been previously exposed to and produce the appropriate 
antibodies to fight the invader upon re-exposure to the pathogen. This project focuses on 





 The immune response can be a double-edged sword when it comes to detecting and 
fighting cancer. Cancer detection can be particularly difficult for the immune system because 
these cells, though they are malignant, are still technically recognized as “self” cells, thus 
making them difficult to identify as foreign and dangerous to the body. Earlier studies have 
identified that the body does eventually produce antibodies that are specific to the proteins 
associated with their individual tumors (Stockert et al. 1998). However, this study showed that 
this phenomenon only occurred in a small portion of the skin, ovarian, lung, breast, and colon 
cancer patients, with only 25 of the 234 patients in the study, or just over 10%, developing anti-
tumor immunity (Stockert et al. 1998). These antibodies were detected via an enzyme-linked 
immunosorbent assay, or ELISA. This type of assay is used in many different areas of healthcare 
and immunology and is not limited just to cancer. ELISA allows us to separate, measure, and 
identify the cellular components of blood serum. Furthermore, we cannot rely on antibody 
therapy for cancer due to the difficulty in targeting different forms of cancer with distinct protein 
signatures. Not only would this require the development of better detection systems, including 
highly specific ELISAs like the ones utilized in this study, but it would require a large 
investment of time, research space, and money, all of which are in short supply during the 
COVID-19 pandemic.  
 
One of the largest regulators of tumor growth and proliferation is the inflammatory 
response within the tumor microenvironment. It has been shown that in an environment with 
chronic inflammation, whether caused by consistent infections, prolonged inflammatory 
responses, or autoimmune issues, tumors are more likely to form. Once tumors have formed, 
they are able to efficiently grow and may have the capability of invading surrounding tissues. 
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Invasion is facilitated by angiogenesis, the formation of blood vessels that contribute greatly to 
metastasis via the bloodstream (Goradel et al. 2021). For example, individuals that abuse alcohol 
consistently show chronic inflammation in their livers and pancreases and have higher rates of 
liver and pancreatic cancer (Lin and Karin 2007). The “double-edged sword” in this case is that 
the inflammatory response is the body’s attempt to fight off the infection, while unknowingly 
providing support for cancer cells and their ability to migrate and invade other areas in the body.  
 
 The primary regulators of the inflammatory response are signaling molecules known as  
cytokines. There are several different cytokines associated with the tumor microenvironment, 
most of which are proinflammatory and therefore pro-tumorigenic. The most well-characterized 
cytokine associated with tumor proliferation is the pro-inflammatory cytokine tumor necrosis 
factor-alpha, shortened to TNF-α, which activates the nuclear factor kappa-chain-enhancer for B 
cells, or NF-kB, kinase signaling pathway (Karin 2006). NF-kB is a transcription factor which 
regulates the expression of genes that play a role in reducing tumor cell apoptosis, tumor cell 
cycle progression, and plays a key role in metastasis (Karin 2006) .  This molecule is released 
from both tumor cells and host immune cells, including macrophages. This cytokine is also 
proposed to assist with the initial formation of a tumor by promoting the production of nitric 
oxide (NO) and reactive oxygen species (ROS), which can cause the DNA damage associated 
with the uncontrolled proliferation of cancer cells (Hussain et al 2003). Studies have found that 
genetic polymorphisms that enhance the production of TNF-α are associated with an increased 
risk of several different cancers, including multiple myeloma and cancers of the bladder, liver, 
stomach, and breasts (Mocellin et al 2005). The inverse has also been found in that tumor cells 
treated with an antibody that neutralizes TNF-α showed widespread cancer cell death (Pikarsky 
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et al 2004). IL-6 is another proinflammatory cytokine associated with tumor proliferation and 
resistance to apoptotic molecules. IL-6 acts as a signaling molecule, and triggers the 
phosphorylation and activation of STAT1, which is a tumor growth inhibitor, and STAT3, which 
is a tumor growth promoter (Hodge et al 2005). This means that the function of IL-6 can vary 
widely in the tumor microenvironment and it is likely too unpredictable to use as a target for 
broad-spectrum cancer therapy. Another cytokine that may contribute to tumor progression is IL-
23, which  is  mainly produced by activated antigen-presenting cells and other phagocytic cells, 
and its receptors are mainly found on T-cells, natural killer cells, and natural killer T cells 
(Trinchieri 2003). IL-23 induces the production of IL-17 and promotes inflammation in the end 
stages of cancer. Ongoing studies are also aimed at determining whether IL-23 can induce TNF-
α production by dendritic cells. Dendritic cells, or DCs, are immune cells that act as a bridge 
between innate and adaptive immunity by phagocytosing antigenic material, breaking it down 
into smaller pieces, and presenting those pieces on their surfaces to alert T cells and the rest of 
the adaptive immune system (Trinchieri 2003). In general, numerous studies have indicated that 
many inflammatory cytokines are associated with tumor proliferation and progression.  
 
In response to the detection of a tumor, the body can also produce anti-inflammatory 
cytokines to reduce the likelihood of the tumor to metastasize. One of the most effective of these 
is TRAIL, which is short for TNF-related apoptosis-inducing ligand and is produced by T cells 
and NK cells and is capable of inducing apoptosis in various cancer cell types with minimal 
effects on healthy cells (Lin and Karin 2007). TRAIL can bind to five different receptors, two of 
which are “death receptors” that flag cells for caspase-dependent apoptosis (LeBlanc and 
Ashkenazi 2003)  Mice with TRAIL knockouts or that were treated with antibodies to neutralize 
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the TRAIL produced by their systems showed a much higher chance of developing tumors, 
whether through experimental induction or naturally (Takeda et al 2002). TRAIL likely plays a 
large role in mediating tumors as they occur, but it is limited in its application. Not all tumor 
cells are sensitive to the effects of TRAIL, and if TNF-α has already activated NF-kB in the 
tumor cells, they are already resistant to TRAIL-mediated apoptotic signaling (Luo et al 2004). 
This means that naturally occurring TRAIL cannot be used in its original form for therapy, but a 
recombinant form may be developed that is more effective against more varieties of cancer. 
Another anti-tumorigenic cytokine is IL-10. This cytokine suppresses the immune system, 
reduces inflammation, and inhibits the NF-kB pathway through mechanisms that have yet to be 
characterized by the scientific community (Schottelius et al 1999). The suppressive effect of this 
cytokine means that proinflammatory cytokines such as TNF-α, IL-6, and IL-12 are not 
produced. IL-10 is known for modulating apoptosis and preventing further angiogenesis as it 
promotes the regression of a tumor (Kundu and Fulton 1997). It accomplishes this through a 
downregulation of MHC class I molecule expression, leading to higher rates of natural killer cell 
attacks on cancerous cells (Kundu and Fulton 1997). Like IL-23, IL-12 is another anti-
inflammatory cytokine produced by APCs and other phagocytic cells, and its receptors are found 
on T cells and NK cells. Like IL-23, it also induces a proinflammatory response. Despite this, IL-
12 is associated with tumor reduction. IL-12 has given promising results in laboratory testing, 
with mouse models showing that IL-12 can not only prevent further spread of existing tumors 
but can also cause them to recede back to a smaller size (Trinchieri 2003). This is aided by 
interferon gamma (IFN‐γ), which has a cytotoxic effect on cancer cells and the blood vessels that 
they produce. Despite its efficacy, IL-12 is not safe to use as a human therapy because it can 
induce high levels of IFN‐γ leading to severe side effects for patients and toxicity (Trinchieri 
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2003). Though the body naturally produces these anti-tumor substances, they typically are not 
expressed at levels high enough to overcome a cancerous tumor on their own.  
 
C. Macrophages and Cancer 
 
A large component of the innate immune response is made up of monocytes and their 
descendant cells, macrophages. Macrophages are immune cells that “sample” their surrounding 
environment by consuming substances throughout the body (Mills 2012). In the tumor 
microenvironment, they act as an activator, sampling the material in the area, analyzing it, and 
recognizing whether to deploy either a “fight” or “fix” response. This allows the immune system 
to determine the difference between a wound and an infection. Macrophages exhibit plasticity 
based on environmental stimuli and can be coerced into numerous populations with distinct 
phenotypic markers and functions. Unactivated or ‘naïve’ cells are called M0 macrophages. This 
resting state occurs before they are alerted to a foreign presence and prior to phagocytosis. These 
M0 macrophages polarize into either M1 or M2 macrophages after they encounter and absorb 
environmental material. These two categories of macrophages have opposing functions. M1 
macrophages, or “classically activated macrophages,” support and encourage the immune 
response by producing NO. This chemical inhibits metastasis by preventing tumor cells from 
being able to grow and spread efficiently. This is what Mills (2012) refers to as the “fight” 
response.  M2 macrophages, or “alternatively activated macrophages,” inhibit the immune 
response by preventing pro-inflammatory signaling and producing ornithine, which supports 
repair. However, this response backfires in the TME by encouraging metastasis and 
strengthening bonds between the cancerous tumor cells and the cells and extracellular matrix 
surrounding it instead of healing healthy, normal cells. Therefore, M2 macrophages are 
considered pro-tumorigenic due to their ability to suppress the body’s natural immune response 
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to tumor formation, while M1 macrophages are considered anti-tumorigenic as they support the 
natural immune response. 
 
While M1 macrophages are considered beneficial for the well-being of the body, the 
tumor microenvironment is rich in IL-10, a cytokine which promotes polarization of monocytes 
into M2 macrophages (Sica et al 2006). In contrast, tumors do not secrete LPS and IFN-γ, which 
promote polarization of monocytes into M1 macrophages (Sica et al 2006). Cases have been 
observed where tumor-associated macrophages make up to 50% of the mass of the tumor, and 
macrophage levels are used as a biomarker to estimate the severity of cancer (Poh and Ernst 
2018). There are several ways in which tumor-associated macrophages (TAM) promote the 
proliferation of cancer. Not only do TAMs express lower levels of inflammatory cytokines, but 
studies have shown that accumulations of these TAMs can promote endothelial cell migration 
(Sica et al 2006). TAMs can also contribute to tumor growth via stroma formation and the 
formation of new blood vessels through release of platelet-derived growth factor (Sica et al 
2006). Furthermore, TAMs have been shown to form clusters near blood vessels and promote 
more invasive behavior through the secretion of epidermal growth factor  nd other 
chemoattractants that recruit more cancerous cells to the initial tumor location (Yamaguchi et al 
2006). This allows the tumor to strengthen its hold in the initial location and digest the 
extracellular matrix surrounding it. As the tumor entrenches itself in its initial location, it 
prepares for pieces of itself to break off and begin to spread to new locations in the body. 
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D. Podosomes and Extracellular Matrix Degradation  
One of the key means by which M2 macrophages efficiently invade the tumor is through 
the development and use of actin-rich protrusions known as podosomes. Podosomes are made up 
of a dynamic and constantly replaced core of polymerized actin surrounded by proteins 
responsible for adhesion and scaffolding, such as Tks4, Tks5, cortactin, Src, and MT1-MMP, a 
metalloprotease (Murphy and Courtneidge 2012). These podosomes act as contact points 
between macrophages and the ECM surrounding them. There is somewhat of a language debate 
on this topic, specifically on the differences between “podosomes” and “invadopodia.” Murphy 
and Courtneidge (year) describe the two as being essentially the same structure, with the only 
difference being that invadopodia are associated with cancerous cells and podosomes are 
associated with all other cell types. For this reason, I will use the term podosomes, as I am 
focused on this structure in macrophages, not the tumors with which they are associated.  
 
According to Murphy and Courtneidge (2012) the presence of podosomes and 
invadopodia is directly related to the ability of a tumor to metastasize. Though podosomes are 
utilized for other adhesive and degradative purposes, I focus specifically on how podosomes are 
associated with the ability of tumor-associated macrophages to alter the extracellular matrix in 
the tumor microenvironment. They accomplish this using integrin proteins, which facilitate 
communication between the macrophage and the ECM surrounding it (Linder and Aepfelbacher 
2003). After binding to the ECM, these podosomes can pull the matrix apart into smaller pieces, 
which can then be moved to new locations or degraded. Cancerous cells within a tumor help to 
facilitate the formation of podosomes through the secretion of colony-stimulating factor 1, or 
CSF1 (Yamaguchi et al 2006). This cytokine acts as a regulator for the building and distribution 
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of podosomes. Once the formation of new podosomes is stimulated, N-WASP facilitates the 
rapid formation of the dynamic actin core, which results in the cell membrane projections 
associated with macrophages (Yamaguchi et al 2006). These projections, when combined with 
recruited proteins, become podosomes. Tumor cells also produce proteinases, enzymes that 
degrade the extracellular matrix that work in conjunction with podosomes to facilitate metastasis 
of cancer and movement towards the bloodstream (Yamaguchi et al 2006). Therefore, podosome 
formation by macrophages contributes to the metastatic process, but much work is necessary to 
understand the mechanisms by which podosomes promote carcinogenesis. 
 
E. Traditional Cancer Therapies 
There are many different treatments available to patients who have been diagnosed with 
cancer. One of those primary treatments is chemotherapy. Literally translated, chemotherapy is 
“chemical-based therapy.” This type of treatment uses drugs given topically, orally, or 
intravenously that are intended to destroy existing cancer cells and prevent new ones from 
forming (National Cancer Institute 2015). Many of these drugs were developed to combat a 
specific biochemical pathway discovered in the mid-1950s when Charles Heidelburger at the 
University of Wisconsin identified that cancer cells in rats had a greater uracil uptake than 
average (DeVita and Chu 2008). These drugs act as a broad-spectrum treatment for cancer, 
though more specific treatments are being developed that represent modern treatment options for 
patients. 
 
Another common cancer treatment is radiation therapy, or radiotherapy. Approximately 
50% of all cancer patients receive radiotherapy at some point during their treatment (Baskar et al 
2012). Radiotherapy-concentrated X-ray radiation that is used to kill cancer cells and reduce the 
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size of tumors. It accomplishes this by damaging the DNA in the cells, and triggers programmed 
cell death, or apoptosis, which continues for several weeks. There are several different ways that 
this type of therapy can be administered. Radiation can be directed at the body via external 
beams, implanted devices, or liquid drugs that are administered orally or intravenously (National 
Cancer Institute 2015). Not only is radiation effective against a variety of different cancers, but it 
is also one of the most cost-effective cancer treatments, making up only 5% of the total cost of 
cancer care (Baskar et al 2012). The most reported side effect of radiation is fatigue, but many of 
the other side effects are similar to those observed during chemotherapy, including diarrhea, 
nausea, changes in skin, and tenderness (National Cancer Institute 2015). However, radiotherapy 
has the benefit of causing less damage to healthy cells than chemotherapy because healthy cells 
are more capable of repairing DNA damage than cancerous cells (National Cancer Institute 
2015).  
 
One of the more invasive techniques used to treat cancer is surgery. There are several 
surgical options associated with cancer diagnosis and care. First, surgery may be used for 
diagnosis. When a tumor is discovered, it is typically biopsied and analyzed under a microscope 
to observe unusual patterns in cell growth. Surgery is also used to determine what “stage” cancer 
is in, to remove tumors from specific locations in the body, to remove the bulk of a cancer by 
“shaving down” a tumor, to treat pain or systemic effects, to place medical devices, 
reconstructive surgery to restore the appearance and function of the body after treatment, and 
preventative surgery to remove tissue that is likely to become cancer (National Institute of Health 
2015). These different types of surgery options can be combined with other cancer therapies for a 
well-rounded treatment plan.  
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III. Therapeutic Strategies to Target Tumor-Associated Macrophages 
 One of the treatments for cancer that is increasingly being explored is macrophage-
specific therapy. TAMs are key targets because they are highly abundant at basement membrane 
degradation sites and at sites surrounding invading tumors (Poh and Ernst 2018). In breast 
cancer, up to 50% of the tumor mass can be attributed to macrophages (Tariq et al 2017). Not 
only can macrophages act to facilitate cancer metastasis, but they also can be used as a 
biomarker for cancer severity and can guide medical providers in the patient treatment plans. 
Measuring TAM levels for cancer patients can also help identify those who are more likely to 
have positive outcomes when given chemotherapy after surgery because TAMs can be re-
educated to prevent tumor proliferation (Poh and Ernst 2018). Figure 1 shows the different 
strategies employed to target TAMs. These include the prevention of macrophage development 
and recruitment to the tumor site, induction of macrophage re-polarization, targeted cell killing, 
inhibition of angiogenesis, and oncolytic virotherapy. Each of these strategies will be discussed 





Figure 1. An overview of macrophage-targeted cancer therapies, including prevention of macrophage recruitment, 
macrophage repolarization, vascular endothelial growth factor (VEGF) production inhibition, apoptosis induction, 
and oncolytic virotherapy.  
 
A. Preventing Macrophage Production  
 
A macrophage-specific cancer therapy strategy is preventing the development of 
macrophage populations. This technique has been shown in studies to limit tumor growth and 
spread, as well as promote cancer cell response to chemotherapy (Poh and Ernst 2018). Drugs 
such as trabectedin can be used to inhibit the production and release of pro-tumoral cytokines, 
including CCL2 and IL6. Biophosphonates have been shown to have a cytotoxic effect on 
myeloid cells, progenitors for monocytes, which become macrophages when polarized. In 
essence, this class of drugs can be used to prevent the development of macrophages by starting 




B. Preventing Macrophage Recruitment  
Preventing macrophages in the body from associating with malignant tumors represents a 
viable macrophage-targeted treatment strategy. Some of the first potential targets for therapy are 
CCL2 and CXCL12, which facilitate the recruitment of TAMs into the cancer tumor and 
promote polarization to the M2 state (Tariq et al 2017). Obese mice with a CCL2 gene knockout 
showed a significant reduction in macrophage invasion into the tumor tissue and an increased 
production rate of inflammatory cytokines (Tariq et al 2017). The opposite effect was also 
observed in mice that overexpressed CCL2, where more TAM infiltration and reduced cytokine 
production was observed (Tariq et al 2017). Drugs that target these signals have shown 
significant reduction of both tumor growth and metastasis in breast cancer and prostate cancer 
(Poh and Ernst 2018). This makes targeting CCL2 and CXCL12 a viable option for cancer 
therapy. There are already drugs under investigation that take advantage of this pathway. 
Siltuximab (CNTO 328) is an anti-IL-6 antibody that shows reduced tumor vascularization and 
reduced production of macrophage chemoattractants, including CCL2 and CXCL12 (Tariq et al 
2017). Bindarit, which acts as an anti-inflammatory agent, has been shown to inhibit CCL2 
secretion, and therefore the infiltration of macrophages into a tumor, in breast cancer and 
prostate cancer during preclinical trials (Tariq et al 2017). Treatments targeting CCL2 and 
CXCL12 may reduce the effect TAMs have on tumor growth, proliferation, and angiogenesis. 
 
Colony-stimulating factor (CSF) also plays a large role in macrophage recruitment to a 
tumor (Tariq et al 2017). For this reason, CSF, and specifically CSF-1, which is responsible for 
TAM recruitment, must be investigated as a potential therapeutic target. In mouse models with 
CSF-1 blocking, tumor growth rates were reduced, and overall survival likelihood increased. In 
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breast cancer, elevated CSF-1 has been directly correlated with increased tumor vascularization 
and a decreased overall chance of survival. This means that, especially in areas with an already 
large concentration of existing blood vessels, CSF-1 can play a direct role in determining how 
much a tumor can grow and spread via metastasis. The mechanism by which CSF-1 functions is 
better understood than that of CCL2 and CXCL12, hence there are several different types of 
drugs in development and in clinical trials that focus on this specific molecule. Small molecules 
have been discovered that inhibit expression of CSF1R, the receptor that works in conjunction 
with CSF, and have been developed into drugs including Plexxicon and Pexidartinib. Results 
from preclinical trials of Plexxicon (PLX-3397) show that M2 macrophages are significantly 
reduced in the TME and that there is a higher proportion of cytotoxic T cells able to infiltrate the 
tumor and facilitate cell death. Another way to target CSF-1 is through antibodies. Anti M-CSF 
antibody treatment has been shown to inhibit tumor growth by up to 40% in human breast cancer 
cells used in mouse model. It also can reduce the number of TAMs recruited to a tumor entirely, 
of both the M1 and M2 varieties. These treatments have great potential, especially if used in 
conjunction with other, more well-established cancer treatments. Anti-CSF1 combined with 
paclitaxel (PTX), a commonly utilized chemotherapy agent, has been shown to significantly 
decrease tumor progression and improve the efficacy of cytotoxic immune cells in breast cancer.  
 
 Adipocytokines are a class of chemical signaling molecules that are secreted by white 
adipose tissue, which is found subcutaneously throughout the body. These chemicals initiate the 
process of inflammatory cytokine secretion, including CCL2, IL-1, IL-6, and TNF-α, as well as 
contribute to the tissue activation of the NF-kB pathway to induce further inflammatory response 
(Tariq et al 2017). These molecules can be especially important for cancers that occur in fattier 
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areas of the body, especially breast cancer. One of the most well-characterized of these 
adipocytokines is COX-2, which acts as an inflammatory mediator that affects the expression of 
genes associated with cancer and stimulates the formation of prostaglandins, lipids associated 
with injuries. There are several drugs that utilize this pathway and show exciting preliminary 
results. Celecoxib, a COX-2 inhibitor, has been shown to inhibit inflammatory mediators 
including COX-2, angiogenesis, and progression of breast cancer in studies. Curcumin, a known 
anti-inflammatory agent, has also demonstrated efficacy as a potential anti-cancer treatment as it 
suppresses release of IL-6, IL-8, and IL-8 by inhibiting the NF-kB and COX-2 pathways. 
NSAIDS also produce a similar effect, reducing the production of pro-inflammatory pathways. 
Aspirin has been shown to reduce the incidence of epithelial cancers and inhibits the secretion of 
adipokines, CCL2, and PAI-1. Even if adipocytokines are not particularly relevant to every type 
of cancer, their healing potential may be harnessed as a treatment for cancers in high-fat areas.  
 
C. Changing Macrophage Phenotype and Function 
Yet another class of macrophage-specific cancer therapy strategy involves the 
reprogramming of existing pro-tumorigenic macrophages to change them from the M2 pro-
tumorigenic state to the M1 anti-tumorigenic state. Studying the genetic code of M2 
macrophages has allowed scientists to identify genes and signaling pathways that regulate 
polarization. The JMJD3 gene is one potential target identified by gene sequencing. This gene 
acts as a transcription activator for genes associated with the M2 macrophage polarization state 
and becomes a transcription inhibitor for M1 macrophage genes (Tariq et al 2017). This means 
that theoretically, if this gene were knocked out or silenced, there would be more M1 
21 
 
macrophages and fewer M2 macrophages produced. The inhibition of certain genes not only can 
promote the repolarization of macrophages but can also act as a booster for the remainder of the 
immune system (Poh and Ernst 2018). Another therapeutic mechanism under investigation is 
manipulating the expression of PDL1, which is associated with reduced tumor cytotoxicity of 
macrophages (Tariq et al 2017). When IL-10 and TNF-α are produced by activated monocytes, 
PDL1 expression is enhanced (Tariq et al 2017). Studies that blocked the expression of PDL1 
showed enhanced patient immunity against cancer (Tariq et al 2017). Drugs and other treatments 
aimed at reducing the expression of this protein may prove effective with future research. A third 
mechanism for macrophage repolarization under investigation is IFN-β (Tariq et al 2017). 
DMXAA (dimethylxanthenone-4 acetic acid) has been shown in studies to increase the 
repolarization of M2 macrophages to M1 macrophages by upregulating the IFN-β signaling 
pathway (Tariq et al 2017). When T-cells and the rest of the immune system are inhibited or 
reduced, repolarization favors the M1 state. Daclizumab, a drug utilizing CD25-specific 
monoclonal antibodies, has been shown to eliminate T regulatory cell populations, removing 
many of the checkpoints that limit production of immune cells and the repolarization of 
macrophages from M2 to M1 (Tariq et al 2017). These drugs have been used for cancer for years 
and were approved by the FDA for use as a cancer treatment in 2011 (Tariq et al 2017). 
Therapeutic strategies that repolarize M2 macrophages into M1 macrophages instead of killing 
them altogether are favorable for cancer patients as they do not deplete macrophages but coerce 






D. Targeting the Production of Vascular Endothelial Growth Factor  
Vascular endothelial growth factor, or VEGF, induces angiogenesis in tumors (Tariq et al 
2017). VEGF is produced by pro-tumorigenic M2 macrophages. There are several different 
therapeutic approaches available to target VEGF production. VEGF is associated with leptin 
receptors in the body, and treatment of breast cancer cells with leptin receptor repressors leads to 
decreased macrophage production of VEGF (Tariq et al 2017). Further characterization of how 
leptin and VEGF interact with each other may elucidate further development of this technique. 
Another treatment already in use for many cancers is bisphosphonate drugs. These drugs act as 
inhibitors of bone resorption and are capable of inhibiting angiogenesis (Lipton 2008). They are 
already commonly used to strengthen the bones of patients with malignant bone diseases such as 
osteoporosis. These drugs may also have the potential to arrest the cell cycle, induce apoptosis in 
tumor cells, and inhibit metastasis (Lipton 2008). Bisphosphonates are also associated with 
decreasing VEGF production from macrophages. Patients with cancer that had metastasized from 
the initial tumor location to their bones were treated monthly with pamidronate, a 
bisphosphonate drug (Lipton 2008). Their basal VEGF levels were shown to have decreased 
rapidly and significantly at 1-, 2-, and 7-days post-infusion with the drug (Lipton 2008).  
Another drug associated with bone disease and VEGF production is zoledronic acid. 
Patients with metastatic bone disease from breast cancer provided a zoledronic acid infusion 
showed significantly reduced serum VEGF levels 3 weeks after their infusion, fewer skeletal-
related events (bone fractures, spinal cord compression, etc.), and a delayed disease progression 
(Lipton 2008). This discovery led to a study to evaluate whether low dose, weekly zoledronic 
acid inhibits angiogenesis in patients whose cancer had metastasized to their bones. Patients were 
found to have an overall decrease in circulating VEGF after the first week of treatment, and this 
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suppression continued for the entirety of the 84-day study (Lipton 2008). Zoledronic acid seems 
to be the most promising of the drugs that reduce VEGF production, and it may become a more 
popular treatment for bone cancer in the future. Overall, strategies to decrease the ability of M2 
macrophages to express factors associated with angiogenesis are continuing to be explored as 
effective anti-cancer therapeutics.  
 
E. Depletion of TAMs  
There are several therapeutic approaches that attack and kill M2 TAMs preferentially 
while leaving M1 TAMs relatively unscathed. The first of these approaches is a minigene 
vaccine that targets Legumain, which is coded by the LGMN gene and is only expressed in M2 
macrophages (Tariq et al 2017). This therapy is exciting because of the minimal side effects it 
has, including leaving existing M1 macrophages relatively unharmed. Researchers have 
developed an oral minigene vaccine against mouse expression of Legumain. The minigene 
vaccine strategy works similarly to normal vaccine strategies in that it facilitates a cytotoxic 
immune response to a specific antigen. In this case, the antigen is a small peptide chain that is 
only 8–10 amino acids long (Lewēn et al 2008). This allows for very specific targeting that 
ignores any irrelevant antigen epitopes to prevent unnecessary reactions that would present as 
side effects in patients. This minigene vaccine was tested in syngenic BALB/c mice and was 
determined to successfully inhibit vascularization of breast cancer cells by facilitating a specific 
cytotoxic T cell response (Lewēn et al 2008). These data represent exciting developments in the 
world of immunology and cancer biology as soon we may be able to use a similar vaccine as a 
prophylactic measure to prevent cancerous tumors from forming in the first place.  
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Another mechanism to induce apoptosis in M2 macrophages is through melittin (MEL), a 
component of bee venom, fused with KLA, a mitochondrial membrane-disrupting agent (Lee et 
al 2019). MEL has been shown to bind preferentially to macrophages that express CD206. 
CD206 has been shown to be more highly expressed on M2 macrophages in preclinical cancer 
models and is associated with angiogenesis. In fact, CD206 has historically been used as a 
prognostic indicator for metastasis and general outcomes for lung cancer . Lastly, KLA is a 
naturally occurring protein with antibacterial properties, showing a preference for prokaryotic 
cells while leaving eukaryotic cells unaffected. Once KLA has been absorbed into a cell, the 
mitochondrial membrane is punctured, releasing cytochrome C into the internal environment of 
the cell and inducing cell death. MEL-dKLA, the fused molecule, was shown to decrease M2 
macrophage viability by about half and inhibit further tumor growth in studies using mice with 
subcutaneous tumors. Not only did the tumors not grow, but tumor size and weight were found to 
have decreased in mice who received the MEL-dKLA treatment. In addition, the ratio between 
M1 and M2 macrophages was found to be significantly higher in treated mice than those who 
received control treatments. This approach, like the minigene vaccine, appears to have great 
potential, but requires further research.  
 
F. Oncolytic Virotherapy 
A potential treatment for cancer that works in conjunction with TAMs is oncolytic 
virotherapy. This treatment involves exposing a patient to an oncolytic virus (OV), a specific 
class of viruses, either naturally occurring or human-engineered, that replicates within and 
eventually kills cancer cells while sparing healthy cells from damage (Fukuhara et al 2016). This 
therapeutic approach was previously investigated from 1949–1980 but yielded low success 
because of the lack of genetic tools to downregulate viral pathogenicity (Fukuhara et al 2016). 
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After major strides in the disciplines of virology, immunology, and genetics, as well as the 
development of tools for investigation of oncolytic agents in the 1980s and early 1990s, Matuza 
(1991) showed that a version of the type I herpes simplex virus with modifications to the gene 
coding for thymidine kinase could potentially be used as a therapy for brain cancer. This began a 
resurgence in research on OV and how they can be used to treat cancers.  
 
i. Ongoing OV Research: Vesicular Stomatitis Virus  
My work in the laboratories of Drs. Ahmed and Seals focused on the OV, vesicular 
stomatitis virus (VSV). VSV is associated with disease in cattle and other mammalian livestock 
species but exhibits low virulence in humans. However, its pathogenic mechanisms in cancer 
cells make it potentially useful as an anti-cancer treatment. Wild-type VSV induces programmed 
cell death through an intrinsic pathway, meaning that once a cell is infected, it detects errors 
within itself and begins apoptosis (Hastie and Grdzelishvili 2012). Recombinant forms of this 
virus were initially developed by researchers as vectors for vaccine delivery and were genetically 
engineered to contain mutations in the viral matrix (M) protein, which is responsible for 
inhibiting host transcription and nuclear-cytoplasmic transport of host mRNA through binding 
with nuclear pore components and transcription factors (Kopecky et al 2001).  This leads to the 
suppression of host gene expression in infected cells, including expression of genes in the host 
antiviral immune response, thus promoting viral replication (Ahmed et al 2003). Unlike the wild-
type form, M protein strains of VSV kill through the extrinsic pathway, meaning that cells are 
destroyed from external processes that result in ligands from outside of the cell binding to 
receptors on the cell surface to trigger apoptosis as  compared to internal apoptotic signaling 
(Hastie and Grdzelishvili 2012). Research into this virus and its mechanisms of action are 
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ongoing in the lab of Dr. Ahmed as well as other laboratories interested in developing VSV-
based oncolytic agents and vaccines. Studies have shown that VSV replication is tightly 
controlled by the type I interferon (IFN) response. If a normal cell is infected with VSV,  virus 
replication is attenuated through activation of antiviral genes in the  type I IFN pathway (Ahmed 
et al 2004). However, the type I IFN response pathway is commonly defective in cancer cells, 
thus making them susceptible to virus infection and killing. Therefore, to further increase the 
tumor selectivity of this virus while promoting safety, cancers can be pre-treated with IFNs or 
infected with M protein mutant strains with an ability to induce IFN production in infected cells 
(Ahmed et al 2004). Large strides are being made in this research field, and VSV carries great 
potential as an oncolytic agent.  
Studies in the laboratories of Drs. Ahmed and Seals are currently investigating the use of 
VSV as an anti-cancer agent that has the capability of targeting M2 TAMs. Studies have shown 
that the M protein mutant strain of VSV (rM51R-M virus), can effectively coerce M2 
macrophages to a M1-like proinflammatory state. Furthermore, rM51R-M virus can inhibit 
podosome formation in M2 macrophages, thus having the potential to decrease the metastatic 
potential of cancer cells. The Ahmed and Seals labs seek to investigate the effects of VSV 
infection on macrophages and determining whether VSV can be used to “switch” macrophages 
from their M2 state to their M1 state. This would make them transition from promoting the 
growth and blood vessel formation of the tumor to attacking it. My project in the laboratory was 
focused on the podosomes produced by these macrophages and how their numbers differed when 
the macrophages were infected with the rM51r-M strain of VSV. Preliminary results supported 
my hypothesis that infection with recombinant VSV would reduce the overall number of 
macrophage podosomes produced. I was able to conclude that infection with rM51r-M VSV 
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appears to reduce the pro-tumorigenic activity of macrophages in the tumor microenvironment. 
The next phase of research into this line of inquiry would be to obtain primary immune cells as 
opposed to the THP1 laboratory cell line utilized in our previous experiments and replicate our 
previous studies to determine if this viral strain is also effective in primary cells. Investigations 
using primary immune cells are already underway and will hopefully yield promising results.    
 
ii. The Future of Oncolytic Virotherapy 
As of 2016, several oncolytic viruses have been approved for therapeutic use. In 2015, 
the United States, the European Union, and Australia approved the use of T-vec, a genetically 
engineered oncolytic virus containing two genetic deletions affecting the ability of the virus to 
infect healthy cells and the rate at which the virus replicates once it has infected cancer cells 
(Fukuhara et al 2016). This therapy has been shown to be an effective treatment against several 
different types of cancer. In 2015, reoviruses were classified as “orphan drugs” for ovarian 
cancer, pancreatic cancer, and some brain and spinal cancers, meaning that they are potentially 
useful as pharmaceuticals, but require further study (Fukuhara et al 2016). These viruses are 
naturally occurring, and show enhanced replication in “transformed,” or cancerous, cells than in 
normal cell lines (Fukuhara et al 2016). However, this type of research tends to be underfunded, 
as pharmaceutical companies are reluctant to provide resources to a long-term project that will 
not immediately generate a profit. Despite the financial risks involved, there is a currently 
ongoing clinical trial for using an intravenous injection of a strain of VSV engineered to express 
NIS and human interferon beta as a clinical treatment for certain types of lung, head, and neck 
cancers. I find this really exciting because if this proves to effectively promote tumor regression 
and even promote tumor apoptosis, we could see many other strains of VSV and other oncolytic 
viruses being brought into clinical trial settings. If this form of virotherapy proves to be effective 
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for the non-small cell lung cancer and head and neck squamous cell carcinoma patients in this 
study, it will pave the way for other oncolytic viral therapies that treat other forms of cancer, 
such as breast cancer, small-cell lung cancer, or pancreatic cancer in the future.   
 
Obtaining funding for research and clinical trials is not the only challenge facing 
oncolytic virotherapy. There are also considerations that must be made surrounding safety and 
efficacy of these viruses before they can be widely used as drugs. Firstly, it must be ensured that 
the viruses are safe to use in patients and patients do not suffer for toxic side-effects. Many of 
these viral strains are known to be normally pathogenic, so for approval in humans, the viruses 
must be genetically modified to reduce pathogenicity. However, this approach can be taken too 
far, and a virus may be weakened so much that it is defeated by the patient’s immune system 
before it reaches the bloodstream. There are several different mechanisms to achieve this “happy 
medium,” including immune checkpoint inhibitors, anti-tumor gene insertion into the viral 
genome, and coupling of the virus with other anti-tumor cells, including macrophages (Fukuhara 
et al 2016). Another limitation to oncolytic virotherapy is engineering a strain that can permeate 
between tumor cells from the initially infected cells. To do this, strains that are capable of 
overcoming the tight epithelial junctions of tumor cells that make them resistant to take up larger 
molecules including oncolytic viruses (Goradel et al 2021).  Researchers also must find viruses 
that are able to survive and replicate effectively in hypoxic environments, such as the tumor 
microenvironment (Goradel et al 2021). The largest challenge faced by researchers investigating 
oncolytic virotherapy is that viral dosage and side effects can vary wildly between patients. This 
means that for this approach to work, the treatment plan must be tailored to each case 
specifically, meaning that this treatment requires more time on the part of scientists and 
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physicians and more money to compensate for this on the part of the patient and their insurance 
company. This is especially important for patients who have already received other forms of 
cancer therapy and likely have a compromised immune system because of it. Overall, OVs have 
the potential to be a treatment for cancer but require more research before they can be used as 
safely and regularly as traditional cancer treatments like chemotherapy and radiation. 
 
IV. Conclusions  
Macrophages and other immune cells play an important and necessary role in cancer. 
However, extensive research into how the immune system interacts with cancer shows that the 
immune response is not always beneficial to the patient, sometimes it promotes carcinogenesis. 
Therefore, it is important to understand the complex interaction of immune cells with tumors. In 
the case of macrophages, they represent a major component of the tumor microenvironment and 
studies on how they contribute to tumor growth and metastasis may lead to important 
information on how to harness their power for good. Through the manipulation of various 
factors, pro-tumorigenic macrophage activity can be thwarted. This can occur with drugs that 
prevent the development of macrophages. However, this type of strategy, which depletes 
macrophages, appears to be a “double edged sword” that may leave patients vulnerable to other 
infections. With the existing knowledge in this area, preventing recruitment of macrophages or 
selectively killing M2 macrophages seem like the most likely therapeutic methods. In addition, 
these strategies may lead to minimal side effects on cancer patients compared to traditional 
chemotherapy. There are many possible therapeutic mechanisms to target TAMs, but most 
require further study and characterization before they can safely be used in humans. Future 
research in this area will likely focus on the differences between M1 and M2 macrophages and 
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establishing mechanisms to reduce the M2 macrophage population without inhibiting the 
tumoricidal activity of M1 macrophages. All in all, this is an exciting area of research that will 
likely surge in the coming years, especially following the COVID-19 pandemic. With the 
development of more effective anti-cancer therapies, including those detailed here that target 
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